Other substances

S2X324

An anti-RBD (SARS-CoV-2 Spike) monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

S2X324 is a human monoclonal antibody neutralizing SARS-CoV-2 in vitro. It was identified in a memory B cell of a convalescent patient. It targets RBD (Collier et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Spike protein Spike variant Protein factor In vitro Antibody 		Vero E6-TMPRSS2 cells; SARS-CoV-2 Spike-pseudotyped viruses (including WA1/2020 D614G or Omicron) 49.96

The antibody neutralizes Omicron variant of SARS-CoV-2 in vitro. 

 Dec/23/2021
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Spike protein ACE2 Spike variant Novel compound Biophysical assay Protein factor In vitro Antibody 		sera of vaccinated older adults; HEK293T ACE2- and TMPRSS2-expressing cells; Vero E6 TMPRSS2-expressing cells; (HIV-1) SARS-CoV-2 Spike pseudotyped virus; (MLV) SARS-CoV-2 Spike pseudotyped virus (D614G and Alpha) 49.96

The antibody neutralized Spike (D614G or Alpha)-pseudotyped SARS-CoV-2 in vitro. 

 Mar/11/2021
Export (.csv)